Halozyme's Royalty Engine Lifts Guidance as Patent Win and Deal Flow Widen the Moat

The quarter in numbers

Halozyme reported third-quarter 2026 total revenue of $493.0 million, against $354.3 million a year earlier. The company said the 39% increase was primarily driven by royalty revenue growth and higher product sales. Royalties reached $341.0 million, up 44% from $236.0 million.

Profit grew in step. Operating income was $295.0 million (versus $217.9 million), net income $247.0 million (versus $175.2 million) and GAAP diluted EPS $2.01 (versus $1.43). Adjusted EBITDA was $336.2 million (versus $248.2 million), and non-GAAP diluted EPS was $2.39 (versus $1.72). The company characterised the quarter as record-level for total and royalty revenue.

What drove growth

The company attributed royalty growth to continued sales uptake of ENHANZE partner products launched since 2020, predominantly argenx's VYVGART Hytrulo, Janssen's DARZALEX SC and Roche's Phesgo, in all geographies, plus contributions from other recently launched products. The release gives no product-level royalty split, pricing or volume data, so the relative weight of each franchise cannot be read from the filing.

Royalties accounted for $341.0 million of the $493.0 million total. By our arithmetic, the remaining revenue was about $152.0 million, up from about $118.3 million. The release says only that product sales rose, without breaking out the figure. Its cost-of-sales commentary points to higher bulk rHuPH20 sales.

Costs and margins

Costs rose with the business, and acquisitions added to them. Cost of sales was $82.5 million (versus $55.2 million), which the company tied to bulk rHuPH20 sales. Amortization of intangibles was $29.5 million (versus $17.8 million) after the November 2025 Elektrofi acquisition. R&D was $27.8 million (versus $17.3 million), reflecting Elektrofi and Surf Bio, acquired in the fourth quarter of 2025. SG&A was $58.2 million (versus $46.1 million), reflecting consulting and professional fees, including litigation costs in a patent infringement case, as well as Elektrofi and higher compensation.

On our calculation, operating income was roughly 60% of revenue, against roughly 62% a year earlier. Adjusted EBITDA was about 68% of revenue, against about 70%. Costs therefore grew slightly faster than revenue, though profitability remains very high. The release does not discuss margins directly.

Guidance raised across the board

The company raised all four 2026 ranges, last updated August 6. Total revenue moves to $1.860-$1.925 billion (previously $1.835-$1.910 billion), or 33%-38% growth. Royalty revenue moves to $1.235-$1.255 billion (previously $1.220-$1.245 billion), or 42%-45% growth. Adjusted EBITDA moves to $1.240-$1.290 billion (previously $1.225-$1.280 billion), or 89%-96% growth. Non-GAAP diluted EPS moves to $8.75-$9.05 (previously $8.65-$9.00), or 111%-118% growth.

The increases are modest, $10-25 million at the revenue and EBITDA lines. Adjusted EBITDA and EPS guidance includes about $60 million of new Hypercon and Aerocon investments, and EPS guidance excludes any future share repurchases. The company said revenue growth is primarily driven by royalties and API product sales.

Balance sheet and capital allocation

Cash, cash equivalents, restricted cash and marketable securities were $1.08 billion at September 30, 2026, versus $145.4 million at December 31, 2025. The company said the increase came primarily from convertible note issuance and operating cash generation. The CFO cited completion of $1.5 billion in convertible notes and a "clear path" to retire the remaining 2027 and 2028 notes at maturity.

In the third quarter Halozyme repurchased about 0.8 million shares for $67.2 million, at an average $79.47 per share, bringing 2026 repurchases to $400 million.

Pipeline, partners and the Merck case

The company said three ENHANZE programs, one each with Pfizer, Incyte and argenx, advanced into Phase 1, bringing total products in development to twelve. Pfizer's tilrekimig study began in September. Incyte and argenx each expanded their agreements (argenx to eight targets in total), and Janssen added one oncology target in October. For Incyte, the release specifies an upfront payment plus potential milestones and royalties, but gives no amounts.

Regulatory items include Takeda's BLA filing for TAK-881 in primary immunodeficiency, argenx's sBLA for VYVGART in ocular myasthenia gravis, FDA priority review for Janssen's SC amivantamab in head and neck squamous cell carcinoma, and Roche's FDA approval of Tecentriq/Tecentriq Hybreza in adjuvant dMMR stage III colon cancer.

In October the specialised Dutch patent court found Merck Sharp & Dohme B.V. infringing one of Halozyme's MDASE patents. It enjoined Keytruda Qlex in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, and rejected MSD BV's invalidity arguments. The release does not address financial impact, appeals or proceedings elsewhere.

What to watch

Watch for the product-sales and royalty mix in the fourth quarter, since guidance leans on both. Also watch how the roughly $60 million Hypercon and Aerocon spend shows up in margins, and whether litigation costs persist in SG&A. On the regulatory side, track the FDA's handling of Takeda's TAK-881 filing, argenx's ocular MG sBLA and Janssen's priority-review application; the release gives no action dates. On the legal side, follow whether the Dutch ruling is challenged or leads to further proceedings. Finally, see how the company uses its enlarged cash position between buybacks, organic investment and note retirement.